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Summary. The pharmacokinetic and acute systemic 
haemodynamic effects of a single oral dose of 50 mg car- 
vedilol has been studied in 24 hypertensive patients with 
chronic renal failure. The patients were stratified into 
3 groups according to the creatinine clearance: 1 51- 
90 ml-min-~; I I  26-50 ml. min-1; I I I  425  ml-rain-1. 
The area under plasma level time curve AUC, the 
elimination half-life tl/2, the maximum plasma concentra- 
tion Cm~, the time to peak concentration tm~x were not sig- 
nificantly different between groups, whereas the amount 
of unchanged rug or metabolite xcreted in urine A~ and 
the renal clearance CLR of carvedilol and its metabolites 
M2, M4, M5 were significantly decreased in Group III. 
Blood pressure and heart rate decreased in all 3 groups of 
patients after acute administration of 50 mg carvedilol. 
Mild adverse ffects were reported in 6 patients. Despite a 
decrease in the renal clearance of carvedilol and of its me- 
tabolites with decreasing kidney function, its main phar- 
macokinetic parameters remained unchanged. The pres- 
ent results suggest that the dose of carvedilol need not be 
reduced in hypertensive patients with chronic renal 
failure. 
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Carvedilol is a non-selective /3-adrenoceptor blocking 
drug with vasodilating activity primarily due to c¢~-adreno- 
ceptor blocking properties, and to a minor extent o cal- 
cium channel blocking activity (little or no contribution to 
the antihypertensive effect) at a high concentration [1]. 
The total clearance of carvedilol is 590 ml- min-  1, its renal 
clearance is 4 ml. rain-1, and the distribution volume is 
132 1 [6, 7]. The absolute bioavailability of carvedilol has
been estimated to be 24 %, indicating some degree of first 
pass extraction, and the protein binding is 95 % [6, 7]. 
Carvedilol has been shown to be effective in the treat- 
ment of patients with essential and renal hypertension, 
and angina pectoris [2-5]. Extensive pharmacokinetic 
studies of carvedilol have been done in healthy volun- 
teers, in hypertensive patients and in patients with liver 
cirrhosis, but its pharmacokinetics in hypertensive pa- 
tients with chronic renal failure has only been reported in 
a preliminary paper [6-12]. In addition, little information 
is available in the literature about he pharmacokinetics of 
the metabolites of carvedilol in hypertensive patients with 
chronic renal failure [12]. Pharmacological ctivity is at- 
tributed only to carvedilol metabolites M2, M4 and M5 
(Sponer, unpublished). The chemical structures of car- 
vedilol and its metabolites are displayed in Fig. 1. 
The pharmacokinetics and effects of acute oral admin- 
istration of 50 mg carvedilol in hypertensive patients with 
chronic renal failure of differing severity have now been 
investigated. 
Patients and methods 
Twenty-five hypertensive in-patients with chronic renal failure were 
enrolled in an open multicentre trial to study the pharmacokinetics 
and blood pressure ffects of acute oral administration of a 50 mg 
capsule of carvedilol, after an overnight fast. 
Carvedilolcapsules were supplied by Boehringer Mannheim and 
were taken with 100 ml water, but with no concomitant medication. 
Patients were allowed food and rink after 3 h. One patient was 
withdrawn from the study due to non-compliance. The study proto- 
col was approved by the local Ethics Committee. All patients gave 
their informed consent o the study. A diastolic blood pressure 
95 mm Hg and < 115 mm Hg (measured 3-times on at least 2 oc- 
casions, in the sitting position, after a 10 rain rest) was taken as the 
inclusion criterion. 
The patients were stratified into 3 groups according to their cre- 
atinine clearance: Group I 51-90 ml/min; Group II 26-50 ml/min; 
Group III 4-25 ml/min. Plasma and urine levels of carvedilol and 
metabolites M2, M4, M5 were measured for 72 h after dosing by 
HPLC with fluorometric detection [13]. Systolic (SBP) and diastolic 
blood pressure (DBE Korotkoff Phase V sounds) were measured 
with a sphygmomanometer for 72 h after dosing. Patients were 
asked to remain supine during the first 6 h after the administration f
50 mg carvedilol, so only supine SBP and DBP are available for that 
period. After the first 6 h following intake of carvedilol standing 
blood pressure (data not shown) was measured, too.Supine blood 
pressure was measured after esting supine for at least 15 rain. 
Some characteristics of the patients are given in Table 1. The 
causes of renal failure were chronic gtomerulonephritis (n = 5), 
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Fig. 1. Chemical structure of carvedilol and the carvedilol metabo- 
lites M2, M4, and M5 
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Fig.2. Renal clearance of carvedilol and creatinine clearance of in- 
dividual patients (n = 2@ The correlation between both variables i
characterized by a regression line y = 0.046 x + 0.602, r = 0.628, 
p < 0.001, n = 24 
chronic pyelonephritis (n = 5), diabetes mellitus (n = 4), hyperten- 
sive nephropathy (n = 2), polycystic kidney disease (n = 2), renal 
agenesis (n = 1), membranoproliferafive glomerulonephritis (n = 
1), obstructive nephropathy (n = 1), and unknown & = 3), The pa- 
tients had been hypertensive for 9.2 (7.5) (1-28)y. Concomitant 
medication was nifedipine (n = 17), nitrendipine (n = 3), metopro- 
lol (n = 8), betaxolol (n = 2), propranolol (n = 1), captopril (n = 1), 
enalapril (n = 1), urapidil (n = 1), prazosin (n = 1), minoxidil (n = 
1), clonidine (n = 4), dihydralazine (n = 1), furosemide (n = 11), 
piretanide (n = 1), prednisolone (n = 1), melphalan (n = 1), phe- 
nytoin (n = 1), acetylsalicylic a id (n = 1), levothyroxine (n = 1), 
digitoxin (n = 2), allopurinol (n = 4), pentoxifylline (n = 1), rani- 
tidine (n = 1), pirenzipine (n = 1), methyldopa (n = 1), bromaze- 
pare (n = 1), oxazepam (n = 1), vitamin D3 derivatives (n - 2). No 
patient had clinical or laboratory signs of hepatic failure. 
Non-compartimental kinetic analysis was done, Calculated phar- 
macokinetic parameters were maximum plasma concentration Cm,x, 
time to peak concentration tmnx, terminal elimination half-life tl/;, 
area under the plasma level-time curve extrapolated to infinity 
AUC, area under the plasma level-time curve from time 0 to end of 
experiment AUC, amount of unchanged rug or metabolite x- 
creted in urine in the time interval Ae, and renal clearance CLR. Be- 
fore and 72 h after drug intake an ECG was recorded and safety lab- 
oratory tests (WBC, RBC, serum creatinine, uric a id, potassium, 
sodium, glucose, total proteins, SGOT, SGP% alkaline phosphatase, 
prothrombin time, bilirubin, cholesterol, triglycerides) were done by 
routine laboratory methods. 
Statistical evaluation was done by means of the Mann-Whitney 
"U"-test between Groups II and III only, because the very small 
number of patients in Group I did not permit statistical analysis. 
Data are given as median and range for pharmacokinetic parame- 
ters, and as mean with (SD) for the remaining parameters. 
Resu l ts  
The pharmacokinet ic  parameters  of carvedilol and of the 
metabol i tes M2, M4, and M5 are listed in Table 2. AUC,  
AUC,  Cmax, tlh, tin,× did not differ between the groups, 
whereas the A~ and CLR of carvedilol and of the three me- 
tabolites were significantly" lower in Group I I I  than in 
Group I I  (P < 0.05; Table 2). The lower renal clearance of 
carvedilol and its metabol i tes in Group  I I I  was not due to 
the lower urine flow (urine volume 2296 (919) ml. 24 h-1 
(Group I I)  or 2078 (858) ml. 24 h -  1 (Group II I),  A signifi- 
cant positive correlation between the renal clearance of 
carvedilol and its creatinine clearance is displayed in 
Fig.2, but no correlation between AUC (n = 22) or 
AUC(0-72  h) (n = 24) of carvedilol and creatinine clear- 
ance could be demonstrated. Both patients with the lo- 
west AUC(0-72  h) values (25 or 126 ng- h. ml-1, respec- 
tively), and only those two, were taking vitamin D3 
derivatives as concomitant medication. Blood pressure 
and heart rate were decreased in all 3 groups of patients 
after acute administration of 50 mg carvedilol (Table 3). 
ECG as well as safety laboratory tests were unchanged 
before and after 72 h after administration of 50 mg car- 
vedilol; serum creatinine [mg. dl -  1]; Group  11.33 (0.49) vs 
1.40 (0.26), Group I I  2.40 (0.76) vs 2.30 (0.85), Group I I I  
5.99 (2.88) vs 6.39 (3.57); bil irubin [mg-dl-~]: 10.7 (0.2) vs 
0.7 (0.2), I I  0.7 (0.4) vs 0.6 (0.5), I I I  0.4 (0.2) vs 0.4 (0.2); 
total protein [g- dl- 2] 1 6.8 (1.0) vs 6.6 (1.0), I I  6.6 (0.9) vs 
6.3 (0.9), I f I  6.6 (0.5) vs 6.6 (1.0); prothrombin t ime [%] 
1 101 (2) vs 101 (2), I I  100 (26) vs 103 (12), I I I  93 (12) vs 93 
(11); GOT [U. 1-1] 1 10 (3) vs 9 (3), I I  8 (2) vs 6 (2), I I I  9 (4) 
vs 9 (4); OPT  [U .1-1] 1 18 (10) vs 17 (11), I I  8 (4) vs 8 (5), 
I I I  8 (5) vs 8 (4); gamma-GT [U-1 -~] 1 34 (34) vs 20 (12), 
I I  29 (31) vs 29 (35), I I I  27 (20) vs 25 (8). 
Adverse effect were reported in 6 patients (headache 
n = 1; d i zz iness  n = 2 accompanied in one patient by 
Tab le  L Patient characteristics 
Patient group I II III 
Number 3 9 12 
Age (y) 42 (15) 51 (13) 51 (15) 
Sex f/m 1/2 4/5 5/7 
Body weight [kg] 67 (18) 71 (12) 69 (11) 
Height [cm] 172 (12) 169 (11) 169 (9) 
87 
Table 2. Pharmacokinetic parameters (median and (r ge)) after a single oral dose of 50 mg carvedilol in hypertensive patients with chronic 
renal failure 
Patient group I II III 
n=3 n=9 n :12  
carvedilol 
AUC [ng-h. ml  :] 1320 (1220-1900) 1110 (646-2950) ~ 1060 (140-18t6) ~' 
AUC(0-72 h) [ng. h. ml-1] 1260 (1170-1850) 939 (25-2920) 946 (126-1780) 
Cm~ [rig. ml-~] 318 (291-356) 180 (5-579) 174 (23475) 
tm~ [h] 0.5 (0.5-3.0) 1.0 (0.5-2.0) 1.3 (0.5-4,0) 
t~/2 [hi 21.9 (18.0-27.2) 12.8 (6.0-34.9) ~ 13.4 (4.7-30.3) u 
&(048 h) [%] 0.7 (0.5-0.7) 0.2 (0.0.0.8) 0.1 (0.o-0.3)* 
CLa [ml. min-~] 4.9 (2.3-4.9) 1.9 (0.7-4.8) 0.8 (0.3-3.1)* 
metabolite M2 
AUC(0-72 h) [ng. h. ml 1] 77 (47-144) 57 (28-157)" 62 (17-145) 
C~ [ng.ml -I] 18 (11-19) 13 (4-20) ~ 11 (4-25) 
tmax [h] 1.5 (1.0-3.0) 1.5 (1.0-2.0) a 1.5 (1.0-4.0) 
Ae(0-48 h) [%1 0.07 (0.06-0.08) 0.01 (0.00-0.08) 0.00 (0.00-0.01)* 
CLR [ml. min-I] 7.7 (4.6-10.2) 1.8 (0.2-5.4)" 0.1 (0.0-0.7)* 
rnetabolite M4 
AUC(0-72 h) [ng-h-ml ~] 64 (39-82) 62 (24-129) ~ 54 (14-128) 
C,~,~ [ng.ml -~] 15 (9-21) 12 (8-51)" 14 (4-26) 
tm~ [h] 1.0 (0.5-2.5) 1.3 (0.5-2.0)" 1.3 (0.5-4.0) 
A~(0-48 h) [%1 0.13 (0.10-0.14) 0.03 (0.00-0.12) 0.01 (0.00-0.03) *~
CLR [ml. min 7 ~1 17.0 (16.9-20.6) 3.5 (1.7-t8.8) ~ 1.3 (0.5-3.4) *~ 
metabolite 345 
AUC(0-72 h) [ng. h. ml-z] 53 (47-89) 30 (16-123) ~ 32 (6-70) 
C~,x [ng.m1-1] 14 (13-17) 10 (5-25)" 10 (3-18) 
t,=~ [h] 1.0 (1.0-2.5) 1.3 (1.0-.2.0) ~ 1.3 (0.5-4.0) 
A~(0-48 h) [%] 0.10 (0.08-0.17) 0.02 (0.00-0.17) 0.00 (0.00-0.02) *~' 
CLR [ml .min -~] 15.6 (14.9-1.6.1) 6.3 (1.8-15.7) ~ 0.9 (0.2-3.2) *b 
* P<0.05, ~n = 8, bn = 11, ~n = 10 
nausea; thrombocytopenia, anaemia, leucopenia, small- 
spotted generalized exanthem n = 1; uric acid increase 
n = 1; triglyceride increase n = 1), none was classified as
serious. Using a causality assessment algorithm for ad- 
verse events, dizziness, nausea, headache, and increase of 
triglycerides were thought to be related to carvedilol 
intake, whereas the other reported events eemed to be 
unrelated (e.g. the leukopenia, thrombocytopenia, 
anaemia in one patient was due to pretreatment with mel- 
phalan and prednisolone and the smalbspotted gener- 
alized exanthema in the same patient was probably due to 
pretreatment with ranitidine hydrochloride or concomi- 
tant treatment with allopurinol). 
Discussion 
After oral administration of 50 mg carvedilol to hyper- 
tensive patients with chronic renal failure, renal clearance 
CLR and the percentage renal excretion of carvedilol and 
metabolites M2, M4, M5 were significantly reduced in the 
patient group with the most severe impairment of kidney 
function. However, the main pharmacokinetic parameters 
AUC, AUC(0-72 h), tl/2, Cm~, tmax both for carvedilol and 
metabolites were not different between the patient 
groups. Because of the present results and the known 
small amount of carvedilol and metabolites excreted via 
the kidneys [6, 7], and see [12], a reduction in the dose of 
carvedilol is not thought o be necessary in hypertensive 
patients with c ronic renal failure. 
Hakusui & Fujimaki [12] investigated the pharmaco- 
kinetic effect of 5 to 10 or 20 mg carvedilol in 9 patients 
with varying stages of renal failure; very little information 
about pharmacokinetic parameters was provided. Plasma 
levels of carvedilol and desmethytcarvedilol (metabolite 
M2) did not differ significantly between patients with im- 
paired and normal renal function [12]. In contrast to the 
present results, Hakusui & Fujimaki [12] did not find a de- 
crease in the amount ofunchanged carvedilol excreted in 
the urine in patients with chronic renal failure. This is 
probably explained by the fact that they did not analyze 
subgroups of the patients; in addition, comparison with 
our results is hampered because it appears that 5 mg car- 
vedilot was used in that part of their study. The possible ac- 
cumulation of carvedilol or metabolites during long-term 
administration, although ighly improbable, should be in- 
vestigated in further studies. AUC and terminal half-life 
assessed here were in the same range as reported in 
healthy volunteers and hypertensive patients; AUC 717 
(270) ng-h-ml- ~ [8], 1097 (761) or 1136 (810) ng-h-ml-1 
[9], 1073 (202) or 1595 (324) ng. h. ml-~ [10]; terminal half- 
life tI/z 14.6 (4.0) h [8], 7.0 (1.9) or7.6 (3.9) h [9]; Morgan et 
al. [10] reported ahalf-life of 5.0 (1.2) or 5.3 (0.7) h, but it 
is not clear from their paper whether that half-life repre- 
sents the terminal half-life. The age distribution in the 
above studies was 61 (6) y [8], 45 (10) y [9], and < 50 y (pa- 
tient Group 1) or 65-80 y (patient Group 2) [11]. In con- 
trast to the above results, one study reported an AUC of 
348 ng-ml, h ~ (170-611) and a terminal half-life of 6.4 h 
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Table 3. Supine systolic (SBP), diastoIic blood pressure (DBP), and heart rate (HR) before and 0.5 h, 1 h, 3 h, 6 h, 12 h, and 24 h after a single 
oral dose of 50 mg carvediloI 
Before 0.5 h 1 h 3 h 6 h 12 h 
Group t 
SBP [mmHg] 155 (13) 137 (6) 130 (10) 127 (23) 135 (9) 140 (26) 153 (25) 
DBP[mmHg] 95 (5) 87 (6) 85 (5) 82 (8) 87 (6) 82 (8) 97(13) 
HR [beats/mini 83 (10) 77 (12) 73 (12) 73 (15) 80 (12) 73 (t.2) 68 (12) 
Group H 
SBP [mmHg] 170 (26) 152 (22) 143 (25) 134 (25) 138 (23) 148 (23) 156 (24) 
DBP [mmHg] 98 (21) 88 (t5) 81 (18) 76 (15) 78 (18) 84 (13) 86 (15) 
HR[beats/min] 72 (9) 65 (7) 62 (8) 61 (9) 64 (6) 72 (9) 67 (9) 
Group III 
SBP [mmHg] 177 (26) 163 (24) 150 (27) 144 (29) 140 (27) 159 (28) 163 (37) 
DBP [mmHg] 102 (8) 91 (11) 86 (15) 84 (16) 81 (16) 89 (14) 91 (20) 
HR[beats/min] 82 (9) 80(10) 75 (7) 75 (5) 79 (8) 78 (6) 76 (9) 
(4.1-14.6) in 20 healthy male volunteers [6, 7, 11]. How-  
ever the mean age was 26 (6) y and the healthy controls 
were of over-average size (height 180 (10) cm; weight 77 
(9) kg; body surface 1.96 (0.15) m 2) [6, 7, 11]. Therefore 
those findings cannot confidently be compared with the 
above studies [8-10], or with the present investigation. In 
addition, the results of Morgan et al. [10] appear  to suggest 
that AUC may increase with age. In another study Neuge- 
bauer et al. [14] demonstrated an AUC of 292 ng. h. ml -  1 
after oral administration of 50 mg carvedilol to 10 young 
(mean age 29.5 y) male subj ects, confirming their previous 
results [6, 7,11]. 
In accordance with these results, the effects of oral ad- 
ministration of 50 mg carvedilol on blood pressure and 
heart rate in patients with chronic renal failure seem to be 
comparable to those in essential hypertensive patients [2- 
4]. Since a low AUC of carvedilol and concomitant intake 
of vitamin D~ derivatives appeared to be associated, the 
possible interaction of the two drugs should be examined 
in a further study. 
The rate of adverse ffects in the present study was low 
and none was classified as serious, although a rather high 
dose of carvedilol had been administered. 
In conclusion, the main pharmacokinet ic  parameters  
after a single oral dose of 50 mg carvedilol did not differ 
between patients with different degrees of renal failure, 
despite a decrease in the renal clearance of carvedilol and 
its metabol i tes M2, M4, and M5. 
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